GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.

Détails

ID Serval
serval:BIB_F36B42AA95E7
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
GOOD VISUAL OUTCOME AT 1 YEAR IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH PIGMENT EPITHELIUM DETACHMENT: Factors Influencing the Treatment Response.
Périodique
Retina
Auteur⸱e⸱s
de Massougnes S., Dirani A., Mantel I.
ISSN
1539-2864 (Electronic)
ISSN-L
0275-004X
Statut éditorial
Publié
Date de publication
04/2018
Peer-reviewed
Oui
Volume
38
Numéro
4
Pages
717-724
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
To evaluate baseline and treatment factors influencing the response of pigment epithelial detachment (PED) in patients with treatment-naive neovascular age-related macular degeneration after 1 year of intravitreal anti-vascular endothelial growth factor treatment.
This retrospective consecutive case series study included 104 eyes (94 patients) with treatment-naive neovascular age-related macular degeneration and associated PED >150 μm treated with aflibercept (n = 41) or ranibizumab (n = 63) for at least 1 year. Stepwise linear regression was used to assess factors influencing best-corrected visual acuity and PED response.
At 1 year, the best-corrected visual acuity improved from 20/63 (60.8 ± 15.9 Early Treatment of Diabetic Retinopathy Study letters) at baseline to 20/40 (69.0 ± 15.0 letters) (P = 0.001), and PED maximal height decreased from 370.8 ± 205.6 μm to 238.8 ± 178.5 μm (P = 0.001). Multivariate analysis revealed an association of the visual improvement with lower best-corrected visual acuity at baseline (P = 0.001), the presence of foveal subretinal fluid (P = 0.001), and female gender (P = 0.047). Pigment epithelial detachment height reduction was dependent on higher baseline PED height (P = 0.001) and treatment drug (P = 0.008).
Visual improvement in neovascular age-related macular degeneration with PED was equally achieved with ranibizumab and aflibercept, influenced mainly by baseline best-corrected visual acuity and foveal subretinal fluid. Pigment epithelial detachment height reduction was influenced by baseline height and the treatment drug, favoring aflibercept for a stronger effect. The clinical significance of this result warrants further studies.
Mots-clé
Aged, Aged, 80 and over, Angiogenesis Inhibitors/therapeutic use, Choroidal Neovascularization/drug therapy, Female, Humans, Intravitreal Injections, Male, Middle Aged, Ranibizumab/therapeutic use, Receptors, Vascular Endothelial Growth Factor/therapeutic use, Recombinant Fusion Proteins/therapeutic use, Regression Analysis, Retinal Detachment/drug therapy, Retinal Detachment/physiopathology, Retinal Pigment Epithelium/pathology, Retrospective Studies, Vascular Endothelial Growth Factor A, Visual Acuity/physiology, Wet Macular Degeneration/drug therapy, Wet Macular Degeneration/physiopathology
Pubmed
Web of science
Création de la notice
18/07/2018 15:45
Dernière modification de la notice
20/08/2019 17:20
Données d'usage